Cashu
Revance Therapeutics Gains FDA Approval for RHA® Dynamic Volume in Aesthetic Treatments
3 months ago
Stocks
Health Care
rvnc
Revance Therapeutics
NASDAQ: RVNC
0.00 (0.00%)
3.65
USD
At close at Apr 01, 18:38 UTC
Latest Revance Therapeutics News
prnewswire.com
Revance and Teoxane Announce the FDA Approval of RHA Dynamic Volume for Midface Contour Deficiencies
3 months ago
prnewswire.com
Revance Announces Appointment of Steve Kreider as EVP, Chief Revenue Officer - Aesthetics and Therapeutics
3 months ago
prnewswire.com
Revance Announces Launch of New StriVectin TL Advanced Sculpting Neck & Jawline Mask
4 months ago
prnewswire.com
Revance Celebrates Distribution of One Million Vials of DAXXIFY in the U.S.
7 months ago
prnewswire.com
Revance Launches the Teoxane RHA Collection with Mepivacaine
7 months ago
prnewswire.com
Revance Announces Launch of New PanOxyl Acne Gel Wash and Daytime Invisible Patches
8 months ago
prnewswire.com
Revance Announces Blue Lizard Australian Sunscreen Times Square Takeover to Celebrate National Sunscreen Day
10 months ago
prnewswire.com
Revance Announces Leadership Succession Plan to Support Next Phase of Growth and Innovation
10 months ago
prnewswire.com
Revance Announces Blue Lizard Australian Sunscreen Named the #1 Selling Mineral Sunscreen Brand
11 months ago
prnewswire.com
Crown Laboratories Now Operates Under the Name Revance
about 1 year ago
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.